RGEN: SEC Form 10-Q filed by Repligen Corporation
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for RGEN
Across the 25 sessions after earlier RGEN headlines, the stock closed higher 10 times and lower 15 times, with a median move of 1.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | RGEN | SPY |
|---|---|---|---|
| Oct 30, 2026 | Repligen Announces $1 Billion Private Convertible Senior Notes Transaction | -6.2% | -1.8% |
| Oct 27, 2026 | Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance | -2.4% | +0.6% |
| Oct 13, 2026 | Repligen to Report Third Quarter 2026 Financial Results | +1.7% | -0.0% |
| Sep 9, 2026 | UBS resumed coverage on Repligen with a new price target | -2.1% | -0.5% |
| Aug 26, 2026 | Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference | -0.8% | +0.0% |
| Jul 28, 2026 | Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance | +10.9% | +0.2% |
Quantisnow market dataNASDAQ
RGEN
Repligen Corporation
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 1986
Get push alerts for RGEN
Full RGEN profile on Quantisnow Follow RGEN and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time